Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

First-in-Human Application of Terbium-161: A Feasibility Study Using 161Tb-DOTATOC

Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas Philip Van der Meulen and Cristina Müller
Journal of Nuclear Medicine February 2021, jnumed.120.258376; DOI: https://doi.org/10.2967/jnumed.120.258376
Richard P. Baum
1 Zentralklink Bad Berka;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aviral Singh
2 Zentralklinik Bad Berka, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harshad R. Kulkarni
2 Zentralklinik Bad Berka, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bernhardt
3 Sahlgrenska University Hospital, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Rydén
4 The Sahlgrenska Academy, University of Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Schuchardt
2 Zentralklinik Bad Berka, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadezda Gracheva
5 Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal V. Grundler
5 Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulli Köster
6 Institut Lau Langevin, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Müller
2 Zentralklinik Bad Berka, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Pröhl
2 Zentralklinik Bad Berka, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Rijn Zeevaart
7 South African Nuclear Energy Corporation (Necsa), South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Schibli
8 ETH Zurich, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Philip Van der Meulen
9 Paul Scherrer Institute, Villigen-PSI, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Müller
10 Center for Radiopharmaceutical Science PSI/ETHZ/USZ Paul Scherrer Institute, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

161Tb has similar decay properties as 177Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply 161Tb in a clinical setting and to investigate the feasibility to visualize the physiological and tumor biodistribution of 161Tb-DOTATOC. Methods: 161Tb was shipped from Paul Scherrer Institute, Switzerland, to Zentralklinik Bad Berka, Germany, where it was used for the radiolabeling of DOTATOC. In two separate studies, 596 MBq and 1300 MBq 161Tb-DOTATOC were administered to a 35-year-old male patient with metastatic, well differentiated, non-functional malignant paraganglioma and a 70-year-old male patient with a metastatic, functional neuroendocrine neoplasm of the pancreatic tail, respectively. Whole-body planar γ-scintigraphies were acquired over a period of several days for dosimetry calculations. SPECT/CT images were reconstructed, using a recently-established protocol and visually analyzed. Patients were checked for adverse events after application of 161Tb-DOTATOC. Results: The radiolabeling of DOTATOC with 161Tb was readily achieved with high radiochemical purity suitable for patient application. Planar images and dosimetry provided the expected time-dependent biodistribution of 161Tb-DOTATOC in liver, kidneys, spleen and urinary bladder. SPECT/CT images were of high quality and visualized even small metastases in the liver and bones. Application of 161Tb-DOTATOC was well tolerated and no related adverse events were reported. Conclusion: This study demonstrated the feasibility to image even small metastases after injection of relatively low activities of 161Tb-DOTATOC using γ-scintigraphy and SPECT. Based on this essential first step to translate 161Tb to clinics, further efforts will be directed towards the application of 161Tb for therapeutic purposes.

  • Neuroendocrine
  • Radiopharmaceuticals
  • SPECT/CT
  • Other
  • 161Tb
  • Auger electrons
  • DOTATOC
  • SPECT/CT imaging
  • first-in-human
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First-in-Human Application of Terbium-161: A Feasibility Study Using 161Tb-DOTATOC
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First-in-Human Application of Terbium-161: A Feasibility Study Using 161Tb-DOTATOC
Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas Philip Van der Meulen, Cristina Müller
Journal of Nuclear Medicine Feb 2021, jnumed.120.258376; DOI: 10.2967/jnumed.120.258376

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First-in-Human Application of Terbium-161: A Feasibility Study Using 161Tb-DOTATOC
Richard P. Baum, Aviral Singh, Harshad R. Kulkarni, Peter Bernhardt, Tobias Rydén, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, Ulli Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas Philip Van der Meulen, Cristina Müller
Journal of Nuclear Medicine Feb 2021, jnumed.120.258376; DOI: 10.2967/jnumed.120.258376
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • 18F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as reference standard
  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
  • A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
Show more Clinical Investigations (Human)

Clinical (Oncology: Endocrine/Neuroendocrine)

  • A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
  • Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE
  • The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Neuroendocrine
  • radiopharmaceuticals
  • SPECT/CT
  • Other
  • 161Tb
  • Auger electrons
  • DOTATOC
  • SPECT/CT imaging
  • first-in-human
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire